European point of care diagnostic testing markets

  • 292 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
292
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. European Point of Care Diagnostic Testing MarketsPublished: September 2011No. of Pages: 179Price: $ 3400Point of care testing (POCT) enables diagnostic tests to be performed rapidly while thepatient remains at the point of care facility, such as a hospital, health clinic, doctors officeor another near-patient venue. POCT is rapidly being recognized as a method of providingthe results of the diagnostic tests immediately, rather than waiting hours or even days foroutside lab results to arrive, thus improving patient outcomes. This report analyzes theEuropean market for POCT products, a major component of the overall European in vitrodiagnostics (IVD) category. This study reviews in detail the key sub-segments of the pointof care diagnostics market including: blood glucose, blood gas and electrolytes, rapidcoagulation, cardiac markers, substance abuse, infectious diseases, urine strip, pregnancy,fecal occult, cholesterol, and many others. For each of the individual sub-segments, thisstudy examines the key market drivers and restraints, as well as evaluates the latesttechnological advances. The key feature of the review is a detailed analysis of the revenues,market growth rates and market share for the European market and for each of the selectedgeographic regions, which include: France, Germany, Italy, Spain, the U.K., the Beneluxcountries, Scandinavia and the Rest of Europe (ROE). The analysis surveys almost all of thecompanies known to be marketing, manufacturing or developing instruments and reagentsfor the point of care market in the European market. Each company is discussed inextensive depth with a section on its history, product line, business and marketing analysis,and a subjective commentary of the companys market position. Detailed tables and chartswith sales forecasts and market data are also included.Browse All: Healthcare Market ResearchTABLE OF CONTENTS1. Overview 101.1 About This Report 101.2 Scope of this Report 101.3 Methodology 111.4 Executive Summary 132. Background to the European Market for Point of Care Testing (POCT) 172.1 Background and Definition of Point of Care Testing 172.2 POCT Application Areas 172.2.1 POCT in the Primary Care Environment 17
  • 2. 2.2.2 POCT in the Operating Room 182.2.3 POCT in the Intensive Care Unit (ICU) 182.2.4 POCT in Accident and Emergency (A&E) 182.2.5 POCT in the Patient Transport Setting 182.2.6 POCT in the Home Environment 182.2.7 POCT in the Community 192.2.8 POCT in Sports Medicine 192.2.9 POCT in the Physician’s Office Laboratory (POL)/Home Care Clinic 192.3 Qualitative Market Analysis 192.3.1 Market Drivers 192.3.2 Market Restraints 212.3.3 Advantages of POCT 232.3.4 Disadvantages of POCT 232.4 Regulatory Environment, Issues and Challenges 242.5 Overview of the European Healthcare Systems 272.6 Procurement Process of Point of Care Testing Products 292.7 Secondary Care Structure and Organization within the E.U. 312.8 Product Pricing Policy and Issues 352.9 Technological Advances and Developments 352.9.1 Device Miniaturization and Microfluidic Technologies 352.9.2 Minimally Invasive and Non-Invasive POCT Technologies 352.9.3 Advances in Wireless Technologies 362.9.4 Automation of POCT 362.9.5 Developments in New Genomic Technologies (Genotyping, Haplotyping andSequencingTechnologies) 362.9.6 Advances in Informatics Technologies 382.9.7 Pharmacogenetic Testing 392.9.8 Multi Assay Technologies in POCT 392.10 Future Trends and Developments 403. The European Market for Blood Glucose POCT 413.1 Background to POC Blood Glucose Testing 413.2 Types of Blood Glucose Testing 423.2.1 Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG) 423.2.2 Two-Hour Postprandial Blood Sugar or Two-Hour PC 423.2.3 Random Blood Sugar (RBS) 423.2.4 Urine Glucose Test 423.2.5 Blood Glucose Test Strip 423.2.6 Glycosylated Hemoglobin (HbA1C) 433.2.7 Intravenous Glucose Tolerance Test (IVGTT) 433.2.8 Oral Glucose Tolerance Test (OGTT) 433.3 Segmentation of POC Blood Glucose Testing 433.3.1 Continuous Blood Glucose Monitoring (CBGM) 433.3.2 Self-Monitoring Blood Glucose (SMBG) Testing 443.3.3 Minimally Invasive and Non-Invasive Blood Glucose Testing 443.4 Emerging Glucose Monitoring Technologies 443.4.1 Optical Transducer Technologies 453.4.2 Transdermal Sensor Technologies 463.4.3 Invasive Glucose Sensor Technologies 47
  • 3. 3.5 Review of Selected POC Blood Glucose Monitoring Systems 473.6 Market Revenue Analysis 513.6.1 European Market Revenues Analysis 513.6.2 National Market Revenue Analysis 523.7 Market Share Analysis 533.7.1 European Market Share Analysis 533.7.2 European Market Share Analysis 544. The European Market for Blood Gas and Electrolyte POCT 584.1 Background to POC Blood Gas and Electrolyte Testing 584.1.1 Acid-base Balance and the Lungs 584.1.2 Respiratory Acidosis 584.1.3 Respiratory Alkalosis 584.1.4 Metabolic (or Non-Respiratory) Acidosis 584.1.5 Metabolic (or Non-Respiratory) Alkalosis 594.1.6 Increasing Popularity of POC Blood Gas and Electrolyte Testing 594.2 Market Segmentation 594.2.1 Types of Blood Gas Monitoring Equipment 594.2.1.1 Intermittent Blood Gas Monitoring Equipment 594.2.1.2 Continuous Blood Gas Monitoring Equipment 594.2.1.2.1 Extra-Arterial Blood Gas (EABG) Monitors 604.2.1.2.2 Intra-Arterial Blood Gas (IABG) Monitors 604.2.1.3 Portable, Blood Gas Analyzers 614.2.1.4 Patient Attached, On-Demand Blood Gas Analyzers 614.3 Applications for POCT Blood Gas and Electrolyte Analyzers 614.4 Qualitative Analysis 614.4.1 Market Drivers 614.4.2 Market Restraints 624.5 Emerging Technologies 624.6 Review of Selected Blood Gas and Electrolyte Analyzers 624.7 Market Revenue Analysis 644.7.1 European Market Revenues Analysis 644.7.2 National Market Revenue Analysis 654.8 Market Share Analysis 654.8.1 European Market Share Analysis 654.8.2 National Market Share Analysis 665. The European Market for Rapid Coagulation Testing 705.1 Background to Rapid Coagulation Testing 705.1.1 Hemostasis 705.1.2 Coagulation 705.1.2.1 The Intrinsic Pathway 715.1.2.2 The Extrinsic Pathway 715.1.3 Activation of Prothrombin to Thrombin 735.2 Blood Coagulation Tests 735.2.1 Bleeding Time Tests 735.2.2 Thrombin Time 745.2.3 The Prothrombin Time (PT) Test 745.2.4 The Partial Thromboplastin Time (PPT) Test 745.2.5 The Fibrinogen Test 75
  • 4. 5.2.6 Standard Test Results 765.3 Qualitative Analysis 765.3.1 Market Drivers 765.3.2 Market Restraints 775.4 Review of Selected POC Rapid Coagulation Analyzers 775.5 Market Revenue Analysis 795.5.1 European Market Revenue Analysis 795.5.2 National Market Revenue Analysis 805.6 Market Share Analysis 815.6.1 European Market Share Analysis 815.6.2 National Market Share Analysis 816. The European Market for POC Cardiac BioMarker Testing 856.1 Background to POC Cardiac Markers Testing 856.2 Cardiac Marker Tests 856.2.1 Creatine Kinase (CK) 856.2.2 Myoglobin 866.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 866.2.4 C-reactive Protein (CRP) 866.2.5 Homocysteine 876.3 Emerging Markers 876.3.1 B-type Natriuretic Peptide (BNP) 876.3.2 Myeloperoxidase (MPO) 876.3.3 Ischemia Modified Albumin (IMA) 886.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 886.3.5 Fatty Acid-Binding Proteins (FABPs) 886.4 Qualitative Analysis 896.4.1 Market Drivers 896.4.2 Market Restraints 896.5 Review of Selected POC Cardiac Biomarkers Analyzers 906.6 Market Revenue Analysis 916.6.1 European Market Revenue Analysis 916.6.2 National Market Revenue Analysis 926.7 Market Share Analysis 936.7.1 European Market Share Analysis 936.7.2 National Market Share Analysis 947. The European Market for POC Substance Abuse Testing 987.1 Background to POC Substance Abuse Testing 987.2 Substance Abuse Test Types 1007.2.1 Urine Substance/Drug Screening 1007.2.2 Hair Tests for Substance Abuse and Screening 1017.2.3 Blood Tests for Substance Abuse and Screening 1017.2.4 Saliva Tests for Substance Abuse and Screening 1017.2.5 Sweat Tests for Substance Abuse and Screening 1017.2.6 Alcohol Abuse and Screening 1017.3 Qualitative Analysis 1027.3.1 Market Drivers 1027.3.2 Market Restraints 1037.4 Review of Selected POC Substance Abuse Analyzers 103
  • 5. 7.5 Market Revenue Analysis 1057.5.1 European Market Revenue Analysis 1057.5.2 National Market Revenue Analysis 1057.6 Market Share Analysis 1067.6.1 European Market Share Analysis 1067.6.2 National Market Share Analysis 1078. The European Market for POC Infectious Disease Testing 1118.1 Background to POC Infectious Disease Testing 1118.2 Types of Diagnosis for Infectious Diseases 1128.2.1 Microbial Culture 1128.2.2 Microscopy 1128.2.3 Biochemical Tests 1128.2.4 Molecular Diagnostics 1128.3 Diagnostic Platforms for Infectious Diseases 1138.3.1 Centralized Laboratory Testing for Infectious Diseases 1138.3.2 POC Testing for Infectious Diseases 1138.4 Emerging Technologies 1148.5 Qualitative Analysis 1148.5.1 Market Drivers 1148.5.2 Market Restraints 1158.6 Review of Selected POC Infectious Disease Testing Devices 1158.7 Market Revenue Analysis 1178.7.1 European Market Revenue Analysis 1178.7.2 National Market Revenue Analysis 1188.8 Market Share Analysis 1188.8.1 European Market Share Analysis 1188.8.2 National Market Share Analysis 1199. The European Market for POC Urine Strip Testing 1239.1 Background to POC Urine Strip Testing 1239.2 Emerging Technologies 1259.3 Review of Selected POC Urine Strip Testing 1259.4 Market Revenue Analysis 1279.4.1 European Market Revenue Analysis 1279.4.2 National Market Revenue Analysis 1289.5 Market Share Analysis 1289.5.1 European Market Share Analysis 1289.5.2 National Market Share Analysis 12910. The European Market for POC Pregnancy Testing 13210.1 Background to POC Pregnancy Testing 13210.2 Review of Selected POC Pregnancy Testing Devices 13210.3 Market Revenue Analysis 13410.3.1 European Market Revenue Analysis 13410.3.2 National Market Revenue Analysis 13410.4 Market Share Analysis 13510.4.1 European Market Share Analysis 13510.4.2 National Market Share Analysis 136
  • 6. 11. The European Market for POC Fecal Occult Testing 13911.1 Background to POC Fecal Occult Testing 13911.2 Review of Selected POC Fecal Occult Testing Devices 14011.3 Market Revenue Analysis 14211.3.1 European Market Revenue Analysis 14211.3.2 National Market Revenue Analysis 14311.4 Market Share Analysis 14411.4.1 European Market Share Analysis 14411.4.2 National Market Share Analysis 14412. The European Market for POC Cholesterol Testing 14712.1 Background to POC Cholesterol Testing 14712.2 POC Cholesterol Testing Devices 14812.2.1 Review of Selected POC Cholesterol Testing Devices 14812.2.2 Product Comparison of Leading Suppliers 14912.2.3 Launch Dates of Leading Products in Europe 15212.3 Market Revenue Analysis 15212.3.1 European Market Revenue Analysis 15212.3.2 National Market Revenue Analysis 15312.4 Market Share Analysis 15312.4.1 European Market Share Analysis 15312.4.2 National Market Share Analysis 15413. Profile of Leading Suppliers 15713.1 Abaxis, Inc. 15713.2 Abbott Laboratories 15913.3 ACON Laboratories, Inc. 16113.4 AgaMatrix, Inc. 16113.5 Alere, Inc. 16213.6 Bayer AG 16413.7 LifeScan (Johnson & Johnson) 16613.8 International Technidyne Corporation (ITC) Nexus Dx (Warburg Pincus, LLC) 16713.9 NOVA Biomedical 16813.10 F. Hoffman-La Roche Ltd. 16813.11 A Menarini Diagnostics 17013.12 Medtronic, Inc. 17113.13 Radiometer Medical (Danaher Corporation) 17213.14 Instrumentation Laboratory (IL)/Werfen Group 17413.15 Siemens 17414. Glossary of Abbreviations and Acronyms 176INDEX OF FIGURESFigure 2.1: Available forms of Connectivity Technology for POCT Devices 22Figure 2.2: Conformity Assessment Route, Annexes and Quality System Standards by IVDDevice Category 25Figure 5.1: The Coagulation Cascade 72Figure 5.2: Coagulation Testing 75
  • 7. INDEX OF TABLESTable 1.1: European Revenue Analysis and Forecasts for POC Market, 2007-2017 13Table 1.2: Segment Revenue Analysis and Forecasts for POC Market, 2007-2017 14Table 1.3: European Revenue Forecasts for POC Market, 2007-2017 15Table 1.4: European Market Share Analysis for POC Market, 2010 16Table 2.1: Total Expenditure on Healthcare, Percentage GDP of Selected Countries, 2002-2008 28Table 2.2: Models of Public-Private Partnership in Hospital Provision 32Table 2.3: Common Genotype Techniques 37Table 3.1: Summary of Emerging Glucose Sensor Technologies, 2011 46Table 3.2: Selected POC Blood Glucose Monitoring Systems, 2011 48Table 3.3: European Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017 52Table 3.4: National Revenue Forecasts by Country for POC Blood Glucose MonitoringSystems,2007-2017 53Table 3.5: European Market Share Analysis for POC Blood Glucose Monitoring Systems,2010 54Table 3.6: French Market Share Analysis for POC Blood Glucose Monitoring Systems, 201054Table 3.7: German Market Share Analysis for POC Blood Glucose Monitoring Systems, 201055Table 3.8: Italian Market Share Analysis for POC Blood Glucose Monitoring Systems, 201055Table 3.9: Spanish Market Share Analysis for POC Blood Glucose Monitoring Systems, 201055Table 3.10: U.K. Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 56Table 3.11: Benelux Market Share Analysis for POC Blood Glucose Monitoring Systems,2010 56Table 3.12: Scandinavian Market Share Analysis for POC Blood Glucose Monitoring Systems,2010 56Table 3.13: Rest-of-Europe Market Share Analysis for POC Blood Glucose MonitoringSystems, 2010 57Table 4.1: Selected POC Blood Gas and Electrolyte Analyzers, 2011 63Table 4.2: European Revenue Forecasts for POC Blood Gas Analysis Systems, 2007-2017 64Table 4.3: National Revenue Forecasts by Country for POC Blood Gas Analysis Systems,2007-2017 65Table 4.4: European Market Share Analysis for POC Blood Gas Analysis Systems, 2010 66Table 4.5: French Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67Table 4.6: German Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67Table 4.7: Italian Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67Table 4.8: Spanish Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68Table 4.9: U.K. Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68Table 4.10: Benelux Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68Table 4.11: Scandinavian Market Share Analysis for POC Blood Gas Analysis Systems, 201069Table 4.12: Rest-of-Europe Market Share Analysis for POC Blood Gas Analysis Systems,2010 69Table 5.1: Selected POC Rapid Coagulation Analyzers, 2011 77
  • 8. Table 5.2: European Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017 80Table 5.3: National Revenue Forecasts by Country for POC Rapid Coagulation AnalyzerSystems,2007-2017 80Table 5.4: European Market Share Analysis for POC Rapid Coagulation Analyzer Systems,2010 81Table 5.5: French Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 201082Table 5.6: German Market Share Analysis for POC Rapid Coagulation Analyzer Systems,2010 82Table 5.7: Italian Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 201082Table 5.8: Spanish Market Share Analysis for POC Rapid Coagulation Analyzer Systems,2010 83Table 5.9: U.K. Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 201083Table 5.10: Benelux Market Share Analysis for POC Rapid Coagulation Analyzer Systems,2010 83Table 5.11: Scandinavian Market Share Analysis for POC Rapid Coagulation AnalyzerSystems, 2010 84Table 5.12: Rest-of-Europe Market Share Analysis for POC Rapid Coagulation AnalyzerSystems, 2010 84Table 6.1: Selected POC Cardiac Biomarkers, 2011 90Table 6.2: European Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017 92Table 6.3: National Revenue Forecasts by Country for POC Cardiac Marker Devices, 2007-2017 92Table 6.4: European Market Share Analysis for POC Cardiac Marker Devices, 2010 94Table 6.5: French Market Share Analysis for POC Cardiac Marker Devices, 2010 94Table 6.6: German Market Share Analysis for POC Cardiac Marker Devices, 2010 95Table 6.7: Italian Market Share Analysis for POC Cardiac Marker Devices, 2010 95Table 6.8: Spanish Market Share Analysis for POC Cardiac Marker Devices, 2010 95Table 6.9: U.K. Market Share Analysis for POC Cardiac Marker Devices, 2010 96Table 6.10: Benelux Market Share Analysis for POC Cardiac Marker Devices, 2010 96Table 6.11: Scandinavian Market Share Analysis for POC Cardiac Marker Devices, 2010 96Table 6.12: Rest-of-Europe Market Share Analysis for POC Cardiac Marker Devices, 2010 97Table 7.1: Selected POC Substance/Drug Abuse Testing Devices, 2011 103Table 7.2: European Revenue Forecasts for POC Substance/Drug Abuse Testing DeviceMarket,2007-2017 105Table 7.3: National Revenue Forecasts by Country for POC Substance/Drug Abuse TestingDevice Market,2007-2017 106Table 7.4: European Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 107Table 7.5: French Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 107Table 7.6: German Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 108Table 7.7: Italian Market Share Analysis for POC Substance/Drug Abuse Testing Device
  • 9. Market, 2010 108Table 7.8: Spanish Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 108Table 7.9: U.K. Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 109Table 7.10: Benelux Market Share Analysis for POC Substance/Drug Abuse Testing DeviceMarket, 2010 109Table 7.11: Scandinavian Market Share Analysis for POC Substance/Drug Abuse TestingDevice Market,2010 109Table 7.12: Rest-of-Europe Market Share Analysis for POC Substance/Drug Abuse TestingDevice Market,2010 110Table 8.1: Selected POC Infectious Disease Testing Devices, 2011 115Table 8.2: European Revenue Forecasts for POC Infectious Disease Testing Devices Market,2007-2017 117Table 8.3: National Revenue Forecasts by Country for POC Infectious Disease TestingDevices Market,2007-2017 118Table 8.4: European Market Share Analysis for POC Infectious Disease Testing Devices,2010 119Table 8.5: French Market Share Analysis for POC Infectious Disease Testing Devices, 2010119Table 8.6: German Market Share Analysis for POC Infectious Disease Testing Devices, 2010120Table 8.7: Italian Market Share Analysis for POC Infectious Disease Testing Devices, 2010120Table 8.8: Spanish Market Share Analysis for POC Infectious Disease Testing Devices, 2010120Table 8.9: U.K. Market Share Analysis for POC Infectious Disease Testing Devices, 2010 121Table 8.10: Benelux Market Share Analysis for POC Infectious Disease Testing Devices,2010 121Table 8.11: Scandinavian Market Share Analysis for POC Infectious Disease Testing Devices,2010 122Table 8.12: Rest-of-Europe Market Share Analysis for POC Infectious Disease TestingDevices, 2010 122Table 9.1: Selected POC Urine Strip Testing, 2011 126Table 9.2: European Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017 127Table 9.3: National Revenue Forecasts by Country for POC Urine Strip Testing ProductsMarket,2007-2017 128Table 9.4: European Market Share Analysis for POC Urine Strip Testing Products, 2010 129Table 9.5: French Market Share Analysis for POC Urine Strip Testing Products, 2010 129Table 9.6: German Market Share Analysis for POC Urine Strip Testing Products, 2010 129Table 9.7: Italian Market Share Analysis for POC Urine Strip Testing Products, 2010 130Table 9.8: Spanish Market Share Analysis for POC Urine Strip Testing Products, 2010 130Table 9.9: U.K. Market Share Analysis for POC Urine Strip Testing Products, 2010 130Table 9.10: Benelux Market Share Analysis for POC Urine Strip Testing Products, 2010 131Table 9.11: Scandinavian Market Share Analysis for POC Urine Strip Testing Products, 2010
  • 10. 131Table 9.12: Rest-of-Europe Market Share Analysis for POC Urine Strip Testing Products,2010 131Table 10.1: Selected POC Pregnancy Testing Devices, 2011 133Table 10.2: European Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017 134Table 10.3: National Revenue Forecasts by Country for POC Pregnancy Testing DevicesMarket,2007-2017 135Table 10.4: European Market Share Analysis for POC Pregnancy Testing Devices, 2010 136Table 10.5: French Market Share Analysis for POC Pregnancy Testing Devices, 2010 136Table 10.6: German National Market Share Analysis for POC Pregnancy Testing Devices,2010 136Table 10.7: Italian Market Share Analysis for POC Pregnancy Testing Devices, 2010 137Table 10.8: Spanish Market Share Analysis for POC Pregnancy Testing Devices, 2010 137Table 10.9: U.K. Market Share Analysis for POC Pregnancy Testing Devices, 2010 137Table 10.10: Benelux Market Share Analysis for POC Pregnancy Testing Devices, 2010 138Table 10.11: Scandinavian Market Share Analysis for POC Pregnancy Testing Devices, 2010138Table 10.12: Rest-of-Europe Market Share Analysis for POC Pregnancy Testing Devices,2010 138Table 11.1: Selected POC Fecal Occult Testing Devices, 2011 141Table 11.2: European Revenue Forecasts for POC Fecal Occult Testing Devices Market,2007-2017 143Table 11.3: National Revenue Forecasts by Country for POC Fecal Occult Testing DevicesMarket,2007-2017 143Table 11.4: European Market Share Analysis for POC Fecal Occult Testing Devices, 2010 144Table 11.5: French Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145Table 11.6: German Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145Table 11.7: Italian Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145Table 11.8: Spanish Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145Table 11.9: U.K. Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146Table 11.10: Benelux Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146Table 11.11: Scandinavian Market Share Analysis for POC Fecal Occult Testing Devices,2010 146Table 11.12: Rest-of-Europe Market Share Analysis for POC Fecal Occult Testing Devices,2010 146Table 12.1: Selected POC Cholesterol Testing Devices, 2011 149Table 12.2: European Revenue Forecasts for POC Cholesterol Testing Products Market,2007-2017 152Table 12.3: National Revenue Forecasts by Country for POC Cholesterol Testing ProductsMarket,2007-2017 153Table 12.4: European Market Share Analysis for POC Cholesterol Testing Products Market,2010 154Table 12.5: French Market Share Analysis for POC Cholesterol Testing Products Market,2010 154Table 12.6: German Market Share Analysis for POC Cholesterol Testing Products Market,2010 154
  • 11. Table 12.7: Italian Market Share Analysis for POC Cholesterol Testing Products Market, 2010155Table 12.8: Spanish Market Share Analysis for POC Cholesterol Testing Products Market,2010 155Table 12.9: U.K. Market Share Analysis for POC Cholesterol Testing Products Market, 2010155Table 12.10: Benelux Market Share Analysis for POC Cholesterol Testing Products Market,2010 156Table 12.11: Scandinavian Market Share Analysis for POC Cholesterol Testing ProductsMarket, 2010 156Table 12.12: Rest-of-Europe Market Share Analysis for POC Cholesterol Testing ProductsMarket, 2010 156Table 13.1: Abaxis, Inc. Net Sales by Business Sector, 2008-2010 158Table 13.2: Abaxis, Inc. Net Sales by Geographic Region, 2008-2010 159Table 13.3: Abbott Laboratories Net Sales by Business Sector, 2008-2010 160Table 13.4: Abbott Laboratories Net Sales by Geographic Region, 2008-2010 160Table 13.5: Alere, Inc. Net Sales by Business Sector, 2008-2010 164Table 13.6: Alere, Inc. Net Sales by Geographic Region, 2008-2010 164Table 13.7: Bayer AG Net Sales by Business Sector, 2008-2010 165Table 13.8: Bayer AG Net Sales by Geographic Region, 2008-2010 165Table 13.9: Johnson & Johnson Net Sales by Major Medical and Diagnostics Businesses,2008-2010 167Table 13.10: Roche Group Net Sales by Business Sector, 2008-2010 169Table 13.11: Roche Group Net Sales by Geographic Region (Pharmaceuticals), 2009 and2010 170Table 13.12: Roche Group Net Sales by Sub-Division (Diagnostics), 2008-2010 170Table 13.13: Medtronic Net Sales by Segment, 2008-2010 172Table 13.14: Danaher Corporation Net Sales by Business Sector, 2008-2010 173Table 13.15: Danaher Corporation Net Sales by Geographic Region, 2008-2010 173About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.com
  • 12. Visit our Market Research Blog